We Bring The Lab Into The Home

Point-of-Care (POC) Lab-on-Chip (LOC) device solution for Chronic Kidney Disease management and assessment.

professionals icon

Finance and Healthcare Professionals

lab on chip icon

Lab-On-Chip Platform Technology for Chronic Disease Diagnosis

cdk icon

Patent Pending Device for Rapid Testing of Chronic Kidney Disease

virtual care platform

Virtual Care Platform for Continued Disease Management

We are a TSX Venture listed reporting issuer and intend to use this public entity to raise the necessary capital to advance and commercialize our first device for Chronic Kidney Disease point-of-care diagnosis and a virtual continued care and education platform for disease management.

We Are Healthcare and Finance Professionals

My Health Logic is solely focused on the Development and Commercialization of its Microfluidic Lab-on-Chip Technology and MATLOC Diagnostic Device for Point-of-Care Digital Assessment and Data Management.

About Us

finance and healthcare professionals
lab on chip

Lab-On-Chip Platform Technology for Chronic Disease Diagnosis

Our Technology is a proprietary lab-on-chip technology clinically validated and patented for CKD assessment

Technology

Patent Pending Device for Rapid Testing of Chronic Kidney Disease

Handheld, non-invasive, low-cost and high accuracy point-of-care diagnostic device

LOC CKD

Chronic Kidney Disease

Chronic KIdney Desase (CKD) or Chronic Renal Desease (CRD) means your kidneys are damaged and loosing their ability to keep you healthy

37M

1 in 7 American adults are estimated to have CKD. It is the 9th leading cause of death in the U.S.

$120b

In Medicare costs, 2017, for all people with all stages of CKD.

90%

Of people who have CKD don’t know they have it.

Leadership

My Health Logic Management Team

Mr. David L. Barthel is an experienced executive leader in the healthcare and medical device space with the proven ability to straddle the worlds of large corporations and early stage businesses. David has coordinated and executed multiple capital fundraising efforts, driving significant revenue growth and has the ability to establish commercial viability across multiple disciplines, strategic partners and sales channels.

Dr. Claudio Rigatto is a Kidney Disease specialist and Associate Professor of Medicine at the University of Manitoba, as well as the Academic Director of the Chronic Disease Innovation Centre.  He has developed POC tests (with Dr Lin) for early detection and risk prediction in CKD, as well as tablet based tools to monitor patient health status at home (telemonitoring).

Harrison brings experience in both public and private capitals markets, enhanced by a strong background in financial reporting. Mr. Ross specializes in equity research and valuation, and has experience in areas of portfolio strategy and asset allocation. He was CFO at DC Acquisition, a Capital Pool Company listed on the TSX.V that raised over $2.5 million and successfully completed its qualifying transaction.

Board of Directors

George was most recently Vice President Finance at Phivida Holdings Inc (VIDA: CSE), a publicly traded company that has raised over $19 million since its IPO in December 2017. He has spent 11 years as an experienced financial controller, working on public companies audits and financial statements to GAAP and IFRS.

Zachary is a corporate finance and advisory professional, specializing in taking companies public. Mr. Stadnyk is currently the Chief Executive Officer and a Director of DC Acquisition Corp

Graydon is a financial professional with diverse experience in the capital markets across a variety of industries. He specializes in corporate finance initiatives and has worked with both

Scientific Development Team

Dr. Francis Lin is the lead inventor of Health Logic’s lab-on-chip technology. Dr. Lin joined the University of Manitoba and is currently a tenured Full Professor in Physics, Immunology and Biological Sciences.

A physician scientist with expertise in clinical nephrology, CKD, health economics, and health systems design.

A epidemiologist and clinical nephrologist with expertise in CKD risk prediction and the lead author of the Kidney Failure Risk Equation.

Dr. Wu’s research focuses on developing microfluidic chips and systems for in vitro cell migration studies and in vitro diagnostics.

Strategic Advisors

Dr. Susy Santos is a diversely experienced leader in healthcare. She is a highly qualified strategic decision-maker in overseeing operations in both clinical and community health services.

Marta is a founder and CEO of a preclinical CRO Radyus Research, focused on early stage product development. Prior to starting Radyus, Marta was the co-founding Partner

Varun Tolani

Varun is a software engineer from Palo Alto, California who holds an MS and BS in Electrical Engineering and Computer Sciences from UC Berkeley. He specializes in artificial intelligence and machine learning and has authored several publications in top-tier artificial intelligence conferences and journals.

Technology

Lab-on-chip technology enables advanced biological sample processing, manipulation and analysis in miniaturized fluidic devices.

Lab-on-chip, point-of-care CKD testing device

Read More

About Us

We are Finance and Healthcare Professionals

We are a TSX Venture listed reporting issuer and intend to use this public entity to raise the necessary capital to advance and commercialize our first device for Chronic Kidney Disease point-of-care diagnosis and a virtual continued care and education platform for disease management.

Who we serve

Stay in touch with us